Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -42.00 -2.18% 1,886.00 1,886.00 1,888.00 1,911.00 1,862.00 1,889.50 304,766 15:00:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,623.2 229.8 91.7 21.7 4,563

Hikma Pharmaceuticals Plc Total Voting Rights

01/04/2019 5:42pm

UK Regulatory (RNS & others)


Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Hikma Pharmaceuticals Charts.

TIDMHIK

RNS Number : 7503U

Hikma Pharmaceuticals Plc

01 April 2019

Hikma Pharmaceuticals PLC

Total Voting Rights and Capital

LONDON, 1 April 2019 - In accordance with the UK Financial Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 March 2019, its share capital consists of 241,629,880 ordinary shares with voting rights. There are nil shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's DTR's.

- ENDS -

Enquiries

 
 Hikma Pharmaceuticals PLC 
 Peter Speirs 
  Company Secretary           +44 20 7399 2760 
 
 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVREAKLFELFNEFF

(END) Dow Jones Newswires

April 01, 2019 12:42 ET (16:42 GMT)

1 Year Hikma Pharmaceuticals Chart

1 Year Hikma Pharmaceuticals Chart

1 Month Hikma Pharmaceuticals Chart

1 Month Hikma Pharmaceuticals Chart
Your Recent History
LSE
HIK
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191213 15:15:14